Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial

详细信息    查看全文

• 作者：Patrizio Vitulo ; MD^a ; Anna Stanziola ; MD^b ; Marco Confalonieri ; MD^c ; Daniela Libertucci ; MD^d ; Tiberio Oggionni ; MD^e ; Paola Rottoli ; MD^f ; Giuseppe Paciocco ; MD^g ; Fabio Tuzzolino ; BS ; PhD^h ; Lavinia Martino ; MD^a ; Marta Beretta ; MD^a ; Adriana Callari ; MD^a ; Andrea Amaducci ; MD^a ; Roberto Badagliacca ; MDⁱ ; Roberto Poscia ; MDⁱ ; Federica Meloni ; MD^e ; Rosa Metella Refini ; MD^f ; Pietro Geri ; MD^c ; Sergio Baldi ; MD^d ; Stefano Ghio ; MD^j ; Michele D&rsquo ; Alto ; MD ; PhD^k ; Paola Argiento ; MD ; PhD^k ; Matteo Sofia ; MD^b ; Mara Guardamagna ; BA(Econ)^l ; Beatrice Pezzuto ; MDⁱ ; Carmine Dario Vizza ; MDⁱ ; ^{dario.vizza@uniroma1.it}
• 关键词：pulmonary hypertension ; chronic obstructive pulmonary disease ; sildenafil ; BODE index ; end-stage lung disease ; lung transplantation
• 刊名：The Journal of Heart and Lung Transplantation
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：36
• 期：2
• 页码：166-174
• 全文大小：682 K
• 卷排序：36

文摘

Pulmonary hypertension (PH) is a well-known independent prognostic factor in chronic obstructive pulmonary disease (COPD) and a sufficient criterion for lung transplant candidacy. Limited data are currently available on the hemodynamic and clinical effect of phosphodiesterase 5 inhibitors in patients with severe PH associated with COPD. This study assessed the effect of sildenafil on pulmonary hemodynamics and gas exchange in severe PH associated with COPD.MethodsAfter screening, this multicenter, randomized, placebo-controlled double-blind trial randomized patients to receive 20 mg sildenafil or placebo 3 times a day (ratio 2:1) for 16 weeks. The primary end point was the reduction in pulmonary vascular resistance. Secondary end points included BODE (body mass index, airflow obstruction, dyspnea, and exercise capacity) index, 6-minute walk test, and quality of life questionnaire. Changes in the partial pressure of arterial oxygen were evaluated as a safety parameter.ResultsThe final population included 28 patients, 18 in the sildenafil group and 10 in the placebo group. At 16 week, patients treated with sildenafil had a decrease in pulmonary vascular resistance (mean difference with placebo –1.4 WU; 95% confidence interval, ≤ –0.05; p = 0.04). Sildenafil also improved the BODE index, diffusion capacity of the lung for carbon monoxide percentage, and quality of life. Change from baseline in the partial pressure of arterial oxygen was not significantly different between the sildenafil and placebo groups.ConclusionsThis pilot study found that treatment with sildenafil reduced pulmonary vascular resistance and improved the BODE index and quality of life, without a significant effect on gas exchange.